Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
OneMedNet, Onco-Innovations and Inka Health Announces Collaboration Aimed to Accelerate Potential for Oncology Drug Development Using Real-World Data and A
-
SYDNEY, April 01, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that the first participant has been treated in the open-label extension (OLE) phase of the XanaMIA trial...
-
JERUSALEM, March 31, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced...
-
MALVERN, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...
-
60 Degrees Pharma (Nasdaq: SXTP) FY25 revenue +65% to $1.0M; improved net loss; continued clinical, commercial, and partnership momentum.
-
Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study140.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1Fabhalta...
-
Arletta Pharma reports >60% clitoral blood flow improvement with Lybrido™ in Phase II study, achieving statistical significance in women with FSIAD.
-
Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected to reach target enrollment (n=300) in April 2026, with topline results expected in the third quarter of 2026Phase 2 IRIS trial for ML-004...
-
ProductLife Group appoints Dr. James Burt as CEO, strengthening global growth and capabilities across regulatory, clinical, quality and digital services.
-
PITTSBURGH, March 23, 2026 (GLOBE NEWSWIRE) -- As GLP-1 therapies reshape obesity care, one biotech company is betting that the root cause of Type 2 diabetes isn’t only excessive weight but a...